New Insights on Alzheimer’s Treatment Risks and Benefits
Recent discussions at the AD/PD annual meeting in Copenhagen have shed light on the complex relationship between the APOE ɛ4 gene variant and Alzheimer’s disease treatments. While carrying two copies of this gene variant has been linked to a higher risk of developing Alzheimer’s and associated brain bleed events, new real-world data from Eisai suggests that the risks may be overstated. Meanwhile, Alzheon is presenting promising findings related to its candidate drug, valiltramiprosate, particularly for patients with mild cognitive impairment.
Understanding Gene Risks in Alzheimer’s Treatments
The APOE4 gene variant has long been associated with an increased risk of Alzheimer’s disease and complications from treatments like Biogen and Eisai’s Leqembi. The European Medicines Agency has even deemed patients who are homozygous for APOE4 ineligible for this groundbreaking therapy due to concerns about amyloid-related imaging abnormalities (ARIA). However, Eisai recently presented data indicating that the incidence of ARIA events in homozygous patients may be lower than previously reported. Their analysis showed that only 21.2% of APOE4 homozygotes experienced ARIA, compared to 13.7% of noncarriers, with most cases being asymptomatic.
In the context of treatment efficacy, Eisai reported that 76% of patients with two copies of APOE4 maintained or improved their disease stage after treatment. This finding suggests that the benefits of Leqembi may outweigh the risks, particularly if patients are treated earlier in the disease process. Eisai’s chief clinical officer, Lynn Kramer, emphasized the importance of understanding these risks to encourage earlier treatment initiation for homozygous patients. The company plans to continue gathering real-world data to potentially revise treatment guidelines for APOE4 homozygous patients.
Dual-Fuel Methanol MAN 175D Announced: Newbuild and retrofit variants planned for 2026
Alzheon’s Promising Developments in Alzheimer’s Research
Alzheon has also made strides in Alzheimer’s research, particularly with its candidate drug, valiltramiprosate. The company presented new data at the AD/PD meeting, highlighting the drug’s potential benefits for patients with mild cognitive impairment (MCI). Previous trials indicated that valiltramiprosate might be particularly effective for those carrying the APOE4 variant, a population that faces significant unmet medical needs due to treatment restrictions. Alzheon’s chief scientific officer, John Hey, noted that the drug has shown a sustained reduction in p-tau-217 levels, a biomarker linked to amyloid pathology, over four years of follow-up.
Importantly, Alzheon’s Phase 3 study revealed no significant difference in ARIA-E rates between the treatment and placebo groups, and even lower rates of ARIA-H in those receiving the drug. This suggests that valiltramiprosate may mitigate some of the risks associated with other Alzheimer’s treatments. Looking ahead, Alzheon plans to conduct further studies to confirm these findings and aims to position the drug as an early intervention for patients showing initial symptoms of Alzheimer’s. The integration of fluid biomarkers into treatment strategies could enhance precision medicine approaches in Alzheimer’s care, providing physicians with better tools for patient management.
